Compare TRNR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | JAGX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 3.9M |
| IPO Year | 2023 | N/A |
| Metric | TRNR | JAGX |
|---|---|---|
| Price | $1.78 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 236.4K | ★ 378.5K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,774,000.00 | ★ $11,785,000.00 |
| Revenue This Year | $578.14 | $22.41 |
| Revenue Next Year | $130.65 | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.36 | 12.45 |
| 52 Week Low | $1.60 | $1.00 |
| 52 Week High | $39.60 | $33.25 |
| Indicator | TRNR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 47.04 |
| Support Level | $1.81 | $1.05 |
| Resistance Level | $2.42 | $1.36 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 18.92 | 70.00 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.